SHANGHAI FOSUN PHARMACEUTICAL GROUPSHANGHAI FOSUN PHARMACEUTICAL GROUPSHANGHAI FOSUN PHARMACEUTICAL GROUP

SHANGHAI FOSUN PHARMACEUTICAL GROUP

No trades
See on Supercharts
Market capitalization
‪58.58 B‬HKD
‪2.65 B‬HKD
‪45.58 B‬HKD
‪480.33 M‬
Beta (1Y)
0.88

About SHANGHAI FOSUN PHARMACEUTICAL GROUP

CEO
De Yong Wen
Headquarters
Shanghai
Employees (FY)
‪40.37 K‬
Founded
1994
ISIN
CNE100001M79
FIGI
BBG001XVDW70
Shanghai Fosun Pharmaceutical Group Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products and medical equipment, import and export of medical equipment, healthcare services, and the provision of related and other consulting services and investment management. It operates through the following business segment: Pharmaceutical Manufacturing and R&D; Healthcare Service; Medical Devices and Medical Diagnosis; Pharmaceutical Distribution and Retail; and Other Business Operations. The Pharmaceutical Manufacturing and R&D segment involves in the production, sale, and research of medicine. The Healthcare Service segment provides healthcare service and hospital management. The Medical Devices and Medical Diagnosis segment focuses on the production and sale of medical equipment and diagnostic products. The Pharmaceutical Distribution and Retail segment issue retail and wholesale of medicine. The Other Business Operations segment comprises business that is different from the role of other segments. The company was founded on January 14, 1994 and is headquartered in Shanghai, China.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 2196 is 11.44 HKD — it has decreased by 0.52% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange SHANGHAI FOSUN PHARMACEUTICAL GROUP stocks are traded under the ticker 2196.
SHANGHAI FOSUN PHARMACEUTICAL GROUP is going to release the next earnings report on Aug 26, 2024. Keep track of upcoming events with our Earnings Calendar.
2196 stock is 1.94% volatile and has beta coefficient of 0.88. Check out the list of the most volatile stocks — is SHANGHAI FOSUN PHARMACEUTICAL GROUP there?
One year price forecast for SHANGHAI FOSUN PHARMACEUTICAL GROUP has a max estimate of 38.00 HKD and a min estimate of 14.50 HKD.
Yes, you can track SHANGHAI FOSUN PHARMACEUTICAL GROUP financials in yearly and quarterly reports right on TradingView.
2196 stock has fallen by 5.61% compared to the previous week, the month change is a 19.21% fall, over the last year SHANGHAI FOSUN PHARMACEUTICAL GROUP has showed a 51.42% decrease.
2196 net income for the last quarter is ‪664.37 M‬ HKD, while the quarter before that showed ‪2.02 B‬ HKD of net income which accounts for −67.07% change. Track more SHANGHAI FOSUN PHARMACEUTICAL GROUP financial stats to get the full picture.
Today SHANGHAI FOSUN PHARMACEUTICAL GROUP has the market capitalization of ‪30.71 B‬, it has decreased by 2.53% over the last week.
Yes, 2196 dividends are paid annually. The last dividend per share was 0.46 HKD. As of today, Dividend Yield (TTM)% is 4.00%. Tracking SHANGHAI FOSUN PHARMACEUTICAL GROUP dividends might help you take more informed decisions.
SHANGHAI FOSUN PHARMACEUTICAL GROUP dividend yield was 1.75% in 2023, and payout ratio reached 27.20%. The year before the numbers were 2.07% and 28.26% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 2196 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SHANGHAI FOSUN PHARMACEUTICAL GROUP stock right from TradingView charts — choose your broker and connect to your account.
2196 reached its all-time high on Aug 5, 2021 with the price of 82.00 HKD, and its all-time low was 10.38 HKD and was reached on Oct 30, 2012.
See other stocks reaching their highest and lowest prices.
As of Apr 20, 2024, the company has ‪40.37 K‬ employees. See our rating of the largest employees — is SHANGHAI FOSUN PHARMACEUTICAL GROUP on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SHANGHAI FOSUN PHARMACEUTICAL GROUP technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SHANGHAI FOSUN PHARMACEUTICAL GROUP stock shows the strong sell signal. See more of SHANGHAI FOSUN PHARMACEUTICAL GROUP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SHANGHAI FOSUN PHARMACEUTICAL GROUP future price: according to them, 2196 price has a max estimate of 38.01 HKD and a min estimate of 14.51 HKD. Read a more detailed SHANGHAI FOSUN PHARMACEUTICAL GROUP forecast: see what analysts think of SHANGHAI FOSUN PHARMACEUTICAL GROUP and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SHANGHAI FOSUN PHARMACEUTICAL GROUP EBITDA is ‪4.64 B‬ HKD, and current EBITDA margin is 10.23%. See more stats in SHANGHAI FOSUN PHARMACEUTICAL GROUP financial statements.